Compare CRL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | AXSM |
|---|---|---|
| Founded | 1947 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.0B |
| IPO Year | 2000 | 2015 |
| Metric | CRL | AXSM |
|---|---|---|
| Price | $217.20 | $177.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $203.58 | $189.57 |
| AVG Volume (30 Days) | 677.1K | ★ 806.9K |
| Earning Date | 02-18-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,023,704,000.00 | $561,263,000.00 |
| Revenue This Year | N/A | $67.10 |
| Revenue Next Year | $1.70 | $58.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 65.83 |
| 52 Week Low | $91.86 | $86.99 |
| 52 Week High | $228.88 | $184.40 |
| Indicator | CRL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 64.78 |
| Support Level | $214.11 | $172.05 |
| Resistance Level | $227.51 | $179.00 |
| Average True Range (ATR) | 7.17 | 7.51 |
| MACD | 0.04 | 0.33 |
| Stochastic Oscillator | 72.15 | 81.87 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.